MIRM Mirum Pharmaceuticals Inc

$MIRM looks like phase 3 news is coming out here tomorrow morning. Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases "today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia."

$MIRM Apparently Alfasigma prices Lynavoy at 80K per year net. Lynavoy is the only competitor for volixibat and this is much higher than expected. If payers accept this price for all patients this would mean volixibat is going to be a multibillion product, even if FDA delays it.

$MIRM this is manipulation in a stock with low volume with institutional owners. It happens all the time. We can be sure there is already a bid in the background (they are possibly using the volixibat temporary weakness after initial FDA discussions) We should NOT take a bid around 130.

$MIRM wow some crazy manipulation is going on here. An FDA approval and 2 positive phase 3 read outs and we are still down 10-30%..

$MIRM - convincing phase 3 win in biliary atresia, highly competent mgmt team continues to execute

$MIRM makes me feel better that an insider bought. I know it was a stock option, but the price he paid was $86. Must feel good about something to go through with buying it.

$MIRM About the same path as from 25 to 80+: • grow your approved products: Livmarli, Ctexli, Atebrioz • add new products: voli and brelo have good results, 3379 may join them • beat larger competitors, like Ipsen, who lost both in marketing and in development. • do interesting BD deals.

$MIRM gives a solid entry point if this keeps selling off. IMO take over target . Very derisked .

$MIRM the good thing is that a share can’t be worth less than 0! 😃 We need pos news around volixibat/FDA talks and the NDA! 💪

$MIRM Mirum (brelo) vs Vir data (tove + eleb combo). Importantly, Mirum placed no limits on the baseline ALT levels and had 17-20% percent of patients with ALT>5x ULN vs 0% in Vir’s trial. • At 24 weeks, Mirum’s P3 vs Vir’s P2 ✓Combined response (Virologic + ALT), registrational endpoint: 56% (weekly dosing), 45% (monthly dosing) vs 47% ✓Virologic response: 86% (weekly dosing), 85% (monthly dosing) vs 100% ✓Safety, flu-like symptoms: 5% (weekly dosing), 11% (weekly dosing) vs 66% • At 48 weeks, Mirum’s P2 vs Vir’s P2 ✓Combined response (Virologic + ALT), registrational endpoint: 55% (weekly dosing), 55% (monthly dosing) vs 56% ✓Virologic response: 95% (weekly dosing), 95% (monthly dosing) vs 97% • Mirum so far has → Same or better efficacy on the registrational endpoint despite about 20% severe patients in the trial. → Comparable efficacy on virologic response considering inclusion of severe patients. → Much better safety

$MIRM this is trading at it’s best in a bio stock. We will be cash pos 2028 latest. Will take some time before we see fruit from these seeds, thats why down together with market today, traders don’t have time, institutions already there. Eventually back to 130 🤩

The FDA approved Mirum Pharmaceuticals’ zilurgisertib, marketed as Atebrioz, to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder in which bone progressively forms in muscles, tendons and ligaments, restricting movement and potentially causing severe disability. Atebrioz is a once-daily oral treatment approved for patients aged 12 and older. The drug works by blocking ALK2, a protein that is abnormally active in most FOP patients and plays a key role in driving the formation of bone outside the normal skeleton. The recommended dose is 100 milligrams. The approval gives Mirum a new treatment option for a rare and debilitating condition for which abnormal bone growth can progressively limit mobility and affect patients’ quality of life. The company’s regulatory milestone also expands its portfolio of therapies targeting uncommon diseases. $MIRM

💊 $MIRM Last trading day before the FDA decision on zilurgisertib, its oral ALK2 inhibitor for FOP. Approval could give Mirum a fourth marketed therapy, with a Q4 launch planned. - Currently sitting on both horizontal + diagonal support 👀 - $138.21 1 year average analyst PT. ~55% upside.

$MIRM, a rare-disease drugmaker, said LIVMARLI met its primary itch endpoint (p=0.0004) in the 52-patient Phase 3 EXPAND trial in ultra-rare liver diseases including biliary atresia. Diarrhea, already a labeled side effect, hit 64% on drug vs 11.1% on placebo; Grade 3+ adverse events were 24.0% vs 22.2%. All 5 secondary endpoints were also met. LIVMARLI is its top seller: $128.7M of $176.2M Q2 2026 sales; 2026 sales guidance is $680M-$700M. Next: a US sNDA in the first half of 2027. Shares closed $85.96 on Oct 9, 2026.

$MIRM i dont get whats going on here. I get that theres a delay on the BLA for Volixibat, but that was known already prior to the recent updates.

$MIRM $INCY Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The recommended dose of Atebrioz is 100 mg administered orally, once daily.

Best real binary $MIRM Best retail momentum candidate $IMRX Best balance sheet among the cheap names $CCCC Highest rug risk $BFRI

$MIRM only getting stronger yet share price is dropping dont get fooled know what you own and keep adding on dips the share price belongs in the $175+ the science has not changed!

$MIRM MIRM hit endpoints Mirum Says Phase 3 EXPAND Met Primary Endpoint For LIVMARLI In Ultra-Rare Cholestatic Liver Diseases

$MIRM FDA approved Atebrioz (zilurgisertib) Friday, the once-daily FOP pill Mirum licensed from Incyte in April. Launch is set for October; pricing comes at launch. The trial data: 63 patients, 100 mg daily for 24 weeks. New bone growth averaged a decrease of 3.2 cm3 vs an increase of 24.6 cm3 on placebo. It is the third approved FOP therapy after Ipsen's Sohonos (2023) and Regeneron's Pasatru (August). The differentiator is convenience: Pasatru is an IV infusion every 4 weeks limited to adults; Atebrioz is a pill approved down to age 12. The commercial question is the pool: about 900 patients worldwide, 300 in the US. Mirum's CEO told Fierce more patients are on clinical studies than commercial drugs, which he reads as unmet demand rather than saturation. For Incyte the prize is a milestone and royalties on a small base. For Mirum, a 5.8B company trading well below its 52-week high, this is the franchise expanding.